Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

• Phase: Phase 2

Details

• Lead Sponsor: Palatin Technologies
• Collaborator: King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
• Treatments: alpha-MSH

Criteria

Inclusion Criteria:

• Post menopausal and in general good health

• In a stable relationship with a male partner for at least 6 months

• Willing to attempt sexual activity once a week with your partner